Compare Amphastar Pharmaceuticals Inc (AMPH) vs JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs JPMorgan Nasdaq Equity Premium Income ETF — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while JPMorgan Nasdaq Equity Premium Income ETF trades at $59.89. The key difference: JPMorgan Nasdaq Equity Premium Income ETF is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | JEPQ | |
|---|---|---|
Market Cap | $863.95M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $30.81 | $61.46 |
52-Week Low | $16.87 | $53.77 |
Enterprise Value | $1.26B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
JEPQ trades at $59.74, up 0.67% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF focuses on Nasdaq-linked covered call strategies for income, with recent dividends including $0.70 in July 2026. Support and resistance cluster tightly around $59-$60, indicating consolidation near current levels.
Outlook remains income-focused with steady distributions, though tax implications and Nasdaq volatility pose risks. Institutional interest is strong, but overbought RSI signals caution for near-term entries. The strategy appeals to retirees seeking monthly cash flow but may lag in strong bull markets due to capped upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About JPMorgan Nasdaq Equity Premium Income ETF
JEPQ seeks to provide monthly income and exposure to the Nasdaq-100 Index with less volatility. It uses a methodology that combines high-growth tech stocks with an options strategy to capture income.
Read more on JEPQ →
